Lack of association of matrix metalloproteinase-3 gene polymorphism with susceptibility to rheumatoid arthritis: a meta-analysis

BMC Musculoskeletal Disorders

Juan Li¹  Zhengzhi Wu³  Zhuanghong Chen²  Guochao He²  Zhitao Feng⁴ 

[1] Department of Traditional Chinese Internal Medicine, School of Traditional Chinese Medicine, Southern Medical University, 1838 North of Guangzhou Road, Guangzhou, China;Department of Orthopedic Surgery, Wuhan General Hospital of Guangzhou Military Command, 627 Wuluo Road, Wuhan, China;The First Affiliated Hospital of Shenzhen University, 3002 West of Sungang Road, Shenzhen, China;School of Medicine, Jinan University, 601 West of Huangpu Road, Guangzhou, China

关键词: Meta-analysis;    Susceptibility;    Polymorphism;    Matrix metalloproteinase;    Rheumatoid arthritis;   

Others  :  1092014
DOI  :  10.1186/1471-2474-15-376

 received in 2014-01-19, accepted in 2014-10-15,  发布年份 2014

【 摘 要 】

Background

Epidemiological studies have investigated the association between matrix metalloproteinase-3(MMP-3) gene-1171 5A/6A polymorphism and rheumatoid arthritis (RA), but the results were inconsistent. To evaluate the specific relationship, we performed a meta-analysis to clarify the controversies.

Methods

The relevant literatures dated to December 07th 2013 were retrieved from PubMed, EMBASE and the China National knowledge Infrastructure (CNKI) databases. The number of the alleles and genotypes for MMP-3 were obtained. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the association between MMP-3 5A/6A promoter polymorphism and RA. All of the statistical analyses were conducted by STATA11.0 software.

Results

A total of 6 case-control studies covering 1451 cases and 1239 controls were included in the final meta-analysis. There was no significant association between MMP-3 5A/6A promoter polymorphism and RA in all genetic models (for 6A versus 5A: OR = 1.19, 95% CI = 0.91-1.56, P = 0.203; 5A/6A versus 5A/5A: OR = 1.31, 95% CI = 0.89-1.92, P = 0.174; 6A/6A versus 5A/5A: OR = 1.78, 95% CI = 0.68-4.61, P = 0.238; the recessive model: OR = 1.48, 95% CI = 0.88-2.47, P = 0.141; and the dominant model: OR = 1.46, 95% CI = 0.71-3.00, P = 0.299). In the subgroup analysis by ethnicity, we obtained the similar results.

Conclusions

We systematically investigate the association between MMP-3-1171 5A/6A polymorphism and RA susceptibility; however, the results show a lack of correlation. Considering the small sample size and the selection bias existed in some studies, further studies are needed to confirm the findings.

【 授权许可】

   
2014 Feng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
• [2]Cooles FA, Isaacs JD: Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011, 23:233-240.
• [3]Kurko J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z: Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol 2013, 45:170-179.
• [4]Viatte S, Plant D, Raychaudhuri S: Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013, 9:141-153.
• [5]Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, Bresnihan B: Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001, 44:1744-1753.
• [6]Murphy G, Nagase H: Progress in matrix metalloproteinase research. Mol Asp Med 2008, 29:290-308.
• [7]Javaid MA, Abdallah MN, Ahmed AS, Sheikh Z: Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol Belg 2013, 113:381-390.
• [8]Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, Young-Min S, Isaacs JD: Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 2012, 14:R30. BioMed Central Full Text
• [9]Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P: Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:83-88.
• [10]Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T: Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001, 28:22-28.
• [11]Ainola MM, Mandelin JA, Liljestrom MP, Li TF, Hukkanen MV, Konttinen YT: Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta. Clin Exp Rheumatol 2005, 23:644-650.
• [12]Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM: Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995, 73:209-215.
• [13]Humphries SE, Luong LA, Talmud PJ, Frick MH, Kesaniemi YA, Pasternack A, Taskinen MR, Syvanne M: The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coron Angiograph Trial Atheroscler 1998, 139:49-56.
• [14]Munhoz FB, Godoy-Santos AL, Santos MC: MMP-3 polymorphism: genetic marker in pathological processes (Review). Mol Med Rep 2010, 3:735-740.
• [15]Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996, 271:13055-13060.
• [16]Spurr NK, Gough AC, Gosden J, Rout D, Porteous DJ, van Heyningen V, Docherty AJ: Restriction fragment length polymorphism analysis and assignment of the metalloproteinases stromelysin and collagenase to the long arm of chromosome 11. Genomics 1988, 2:119-127.
• [17]Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
• [18]Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, Rothman N, Stroup D, Taiol E, Thomas D, Vainio H, Wacholder S, Weinberg C: Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002, 156:300-310.
• [19]Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Health Research Institute. [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp webcite]
• [20]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [21]Higgins JGS: Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. [http://www.cochrane.org/handbook webcite]
• [22]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [23]Constantin A, Lauwers-Cances V, Navaux F, Abbal M, Van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A: Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002, 46:1754-1762.
• [24]Dorr S, Lechtenbohmer N, Rau R, Herborn G, Wagner U, Muller-Myhsok B, Hansmann I, Keyszer G: Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther 2004, 6:R199-R207. BioMed Central Full Text
• [25]Rodriguez-Lopez J, Perez-Pampin E, Gomez-Reino JJ, Gonzalez A: Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther 2006, 8:R1. BioMed Central Full Text
• [26]Zhou LT, Shen N, Bao CD: Association of Matrix metalloproteinase 3 single nucleotide polymorphism with Rheumatoid arthritis disease and bone erosion. Shandong Med J 2007, 47:38-39.
• [27]Scherer S, De Souza TB, De Paoli J, Brenol CV, Xavier RM, Brenol JCT, Chies JA, Simon D: Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int 2010, 30:369-373.
• [28]Abd-Allah SH, Shalaby SM, Pasha HF, El-Shal AS, Abou El-Saoud AM: Variation of matrix metalloproteinase 1 and 3 haplotypes and their serum levels in patients with rheumatoid arthritis and osteoarthritis. Genet Test Mol Biomarkers 2012, 16:15-20.
• [29]Kirwan JR: Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol 2001, 28:881-886.
• [30]Williams RO, Feldmann M, Maini RN: Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann Rheum Dis 2000, 59(Suppl 1):i75-i80.
• [31]Tanabe N, Maeno M, Suzuki N, Fujisaki K, Tanaka H, Ogiso B, Ito K: IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Life Sci 2005, 77:615-626.
• [32]Mattey DL, Nixon NB, Dawes PT, Ollier WER, Hajeer AH: Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arhtritis. Genes Immun 2004, 5:147-149.
• [33]Tsukahara S, Shinozaki M, Ikari K, Mochizuki T, Inoue E, Tomatsu T, Hara M, Yamanaka H, Kamatani N, Momohara S: Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients. Rheumatology 2008, 47:41-44.
• [34]Nemec P, Pavkova-Goldbergova M, Gatterova J, Vasku A, Soucek M: Association of the 5A/6A promoter polymorphism of the MMP-3 gene with the radiographic progression of rheumatoid arthritis. Ann N Y Acad Sci 2007, 1110:166-176.
• [35]Ye S, Patodi N, Walker-Bone K, Reading I, Cooper C, Dennison E: Variation in the matrix metalloproteinase-3, -7, -12 and -13 genes is associated with functional status in rheumatoid arthritis. Int J Immunogenet 2007, 34:81-85.